Supernus Pharmaceuticals
- Market cap
- 2.51B
- P/E (TTM)i
- -22.42
- P/Bi
- 2.43
- EPSi
- -0.68
- Div yieldi
- 0.00%
- 52W posi
- 13%
Anonymous reader poll. Unscientific, not investment advice.
Supernus Pharmaceuticals last traded at 43.05, up 0.51% on the session. Its market capitalisation is about 2.51B, the #2636 most valuable US-listed company we track. The trailing P/E of -22.31 is 126% below its five-year average of 85.29. The 4 analysts covering the stock are, on balance, at Buy, targeting an average of 65.25 (+52%). Against a 52-week band of 40.51-59.68, the shares are currently 13% of the way up.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 months.
- Its last 5 Sell calls were followed by a 3% average decline over the next quarter.
- Recent price momentum is -10.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 8.6% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 2.5% | Better than 30% |
| Net income CAGR (3Y) | 11.4% | Better than 62% |
| Free cash flow CAGR (3Y) | -26.6% | Better than 10% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 89.6% | Better than 98% |
| Operating margin | -5.1% | Better than 7% |
| Net margin | -5.4% | Better than 8% |
| Return on equity | -3.7% | Better than 12% |
| Return on invested capital | -4.5% | Better than 9% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -10.8% | Better than 26% |
| 6-month return | -16.1% | Better than 15% |
| 12-month return (ex latest month) | -9.9% | Better than 21% |
| Distance below 52-week high | 28.4% | Better than 31% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 65% |
| Debt to assets | 2.8% | Better than 90% |
| Interest coverage | 2.1x | Better than 21% |
| Free cash flow / net income | 231.8% | Better than 86% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 52.6% | Better than 84% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 42.83
- Open
- 42.24
- Day range
- 42.24 - 43.38
- Avg price
- 43.04
- Volume
- 571.04K
- Turnover
- 24.58M
- Turnover ratei
- 1.10%
- Volume ratioi
- 0.59
- Amplitudei
- 2.66%
- 52-week rangei
- 40.51 - 59.68
Valuation
- P/Ei
- -63.31
- P/E (TTM)i
- -22.42
- P/Bi
- 2.43
- EPSi
- -0.68
- Book value / shi
- 17.71
- Net profit
- -39.59M
- Net assets
- 1.03B
Share structure
- Market cap
- 2.51B
- Float capi
- 2.23B
- Shares out
- 58.22M
- Float sharesi
- 51.84M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
27.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.34M net over the window
Short interest
- Shares short
- 4.99M
- % of floati
- 8.57%
- Days to coveri
- 8.65
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Supernus Pharmaceuticals (SUPN)?
Supernus Pharmaceuticals last traded at 43.05. The quote on this page refreshes every few seconds while US markets are open.
What is Supernus Pharmaceuticals's market cap?
About 2.51B.
What is the P/E ratio of Supernus Pharmaceuticals?
The trailing twelve-month P/E is -22.42, below its own 5-year average of 85.29 — toward the bottom of its historical range (22.17% percentile). See the Valuation tab for the full history.
Does Supernus Pharmaceuticals pay a dividend?
Supernus Pharmaceuticals does not currently pay a regular dividend.
Is Supernus Pharmaceuticals a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 65.25, which implies 51.6% upside from the current price. This is not investment advice.
What is Supernus Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Supernus Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 04:02:46 · For reference only, not investment advice and not tailored to your situation.